Pure Global
NCT04724967

CeraVe Diabetes Mellitus

Clinical Evaluation of CeraVe Hydrating Cleanser and Moisturizing Cream for the Improvement of Skin Condition in Patients With Diabetes Mellitus (DM) Related Skin Changes
University of Miami·Phase 4·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetes Complications
Drug/Device/Intervention
CeraVe Hydrating Cleanser
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Miami
Location
Miami, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Mar 12, 2021
End date
Aug 10, 2021
Enrollment
16 participants
Primary outcome

Percentage of participants reporting adverse events (AE),Frequency of participants reporting adverse events (AE),Physician-assessed Global Aesthetic Improvement Scale (GAIS)

Summary

The purpose of this study is to evaluate the safety and efficacy of the CeraVe Diabetic Skin
 Line for the improvement of skin condition in patients with diabetes mellitus.

ICD-10 classifications
Unspecified diabetes mellitus without complicationsOther specified diabetes mellitus with other specified complicationsOther specified diabetes mellitus without complicationsUnspecified diabetes mellitus with other specified complicationsOther specified diabetes mellitus with unspecified complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04724967
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04724967 through Pure Global AI's free database. This Phase 4 trial is sponsored by University of Miami and is currently Completed. The study focuses on Diabetes Complications. Target enrollment is 16 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.